Setting up a COVID-19 Care Facility at a Prison in Pakistan

May 27, 2020 updated by: Usman Ismat Butt, Services Institute of Medical Sciences, Pakistan
Presenting outline of the steps taken by our team to set up a Covid Care facility within the Prison setting. The facility was set up at Camp Jail (Lahore District Jail) located on Ferozpur Road, Lahore.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

A prisoner brought to Camp Jail developed symptoms of and later tested positive for COVID-19. This lead to almost 527 contacts. An outbreak was expected. To manage the situation , a COVID-19 Care Facility was established within the prison. The study describes the steps taken by the team to set up this facility.

Study Type

Observational

Enrollment (Actual)

69

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Pakistan
      • Lahore, Pakistan
        • Camp Jail / COVID-19 CARE FACILITY/ SIMS

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Study population consisted of the prisoners who after being exposed to a suspected COVID-19 patient tested positive on screening. a total of 59 prisoners were detected by screening. They were included in the study. 10 COVID-19 prisoners shifted to Camp Jail were also latter included.

Description

Inclusion Criteria:

- All COVID-19 positive prisoners within the Camp Jail

Exclusion Criteria:

  • Any patient being shifted to any other facility (except designated)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
CASE
59 COVID-19 POSITIVE PRISONERS WHO UNDERWENT TREATMENT AT THE COVID-19 CARE FACILITY AT CAMP JAIL.
Other: COVID-19 FACILITY
A COVID-19 facility was setup within the Prison. All positive prisoners were managed in the facility. If further intervention was required they were to be shifted to Services Hospital , Lahore.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Recovery
Time Frame: 30 days
Confirmed by double negative PCR results of specimen obtained via nasopharyngeal swabs
30 days
Mortality
Time Frame: 30 days
Death of any of the patients who had tested positive at the Camp Jail
30 days
ICU admission
Time Frame: 30 days
Any patient requiring admission to intensive care unit due to developing symptoms
30 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Services Institute of Medical Sciences, Pakistan

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 27, 2020

Primary Completion (Actual)

May 2, 2020

Study Completion (Actual)

May 2, 2020

Study Registration Dates

First Submitted

May 24, 2020

First Submitted That Met QC Criteria

May 24, 2020

First Posted (Actual)

May 27, 2020

Study Record Updates

Last Update Posted (Actual)

May 29, 2020

Last Update Submitted That Met QC Criteria

May 27, 2020

Last Verified

May 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CovJ

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COVID-19

Clinical Trials on COVID-19 FACILITY

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe